AT-56 is a potent, selective and orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS), with an IC50 of 95 μM and Ki of 75 μM. AT-56 could selectively suppress the drowsiness or pain reaction mediated by L-PGDS-catalyzed PGD2.
体外研究
AT-56 (1-30 μM; 10 minutes) dose-dependently inhibits the production of PGD2 in L-PGDS-expressing human medulloblastoma TE-671 cells with an IC50 of about 3 μM.
体内研究
AT-56 ( 1-30 mg/kg; p.o.) suppresses the PGD2 production in the stab-wounded brain.
AT-56 (1-10 mg/kg; p.o.) suppresses the L-PGDS-mediated allergic airway inflammation in mice.
AT-56 (10 mg/kg; p.o.) exhibits Cmax (2.15 μg/ml), half-life (1.71 h) and high oral bioavailability (82%).
Animal Model:
H-PGDS KO mice (14-16weeks, 25-30 g, C57BL/6 strain) with a stab wound brain injury
Dosage:
0, 1, 3, 10, 30 mg/kg
Administration:
P.o. 1 h before the stab wound injury
Result:
Inhibited the L-PGDS reaction in the brain.
Decreased the total amount of PGD2 in the brain to 40% with 30 mg/kg AT-56.
Animal Model:
Human L-PGDS-overexpressing TG mice (males, 14-16 weeks, 25-30 g)
Dosage:
0, 1, 10 mg/kg
Administration:
P.o. 1 h before and 24 h after the antigen exposure
Result:
Prevented the eosinophil infiltration by inhibiting transgened human L-PGDS.
Animal Model:
Male C57BL/6 mice (7 weeks, 22-26 g)
Dosage:
10 mg/kg for p.o. and 2 mg/kg for i.v. (Pharmacokinetic Analysis)